相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Key necroptotic proteins are required for Smac mimetic-mediated sensitization of cholangiocarcinoma cells to TNF-α and chemotherapeutic gemcitabine-induced necroptosis
Perawatt Akara-amornthum et al.
PLOS ONE (2020)
Epigenetic Regulation of RIP3 Suppresses Necroptosis and Increases Resistance to Chemotherapy in NonSmall Cell Lung Cancer
Qiong Wang et al.
TRANSLATIONAL ONCOLOGY (2020)
Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large B-cell lymphoma by stabilizingNOXAand triggering mitochondrial apoptosis
Anna Dietz et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Reduction in MLKL-mediated endosomal trafficking enhances the TRAIL-DR4/5 signal to increase cancer cell death
Se-Yeon Park et al.
CELL DEATH & DISEASE (2020)
Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells
Eun Byeol Jo et al.
BMC CANCER (2019)
The role of necroptosis in cancer biology and therapy
Yitao Gong et al.
MOLECULAR CANCER (2019)
An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence
Kevin Kalisz et al.
INSIGHTS INTO IMAGING (2019)
Prognostic and clinicopathological significance of DEPTOR expression in cancer patients: a meta-analysis
Binwu Hu et al.
ONCOTARGETS AND THERAPY (2018)
Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism
Frank A. Lincoln et al.
CELL DEATH & DISEASE (2018)
The SMAC Mimetic APG-1387 Sensitizes Immune-Mediated Cell Apoptosis in Hepatocellular Carcinoma
Zide Chen et al.
FRONTIERS IN PHARMACOLOGY (2018)
Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy
Meghan Leary et al.
CANCERS (2018)
The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma
Kyle Runckel et al.
BLOOD ADVANCES (2018)
Therapeutic targeting of necroptosis by Smac mimetic bypasses apoptosis resistance in acute myeloid leukemia cells
C. Safferthal et al.
ONCOGENE (2017)
2-HG Inhibits Necroptosis by Stimulating DNMT1-Dependent Hypermethylation of the RIP3 Promoter
Zhentao Yang et al.
CELL REPORTS (2017)
Smac mimetic triggers necroptosis in pancreatic carcinoma cells when caspase activation is blocked
Sabine Hannes et al.
CANCER LETTERS (2016)
Cancer therapy in the necroptosis era
Z. Su et al.
CELL DEATH AND DIFFERENTIATION (2016)
The SMAC mimetic BV6 induces cell death and sensitizes different cell lines to TNF- and TRAIL-induced apoptosis
Mohamed El-Mesery et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2016)
Optimized Sleeping Beauty transposons rapidly generate stable transgenic cell lines
Eric Kowarz et al.
BIOTECHNOLOGY JOURNAL (2015)
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study
Herbert I. Hurwitz et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics
Gi-Bang Koo et al.
CELL RESEARCH (2015)
Promises and Challenges of Smac Mimetics as Cancer Therapeutics
Simone Fulda
CLINICAL CANCER RESEARCH (2015)
A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma
Ravi K. Amaravadi et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Necroptosis and its role in inflammation
Manolis Pasparakis et al.
NATURE (2015)
Smac mimetics as IAP antagonists
Simone Fulda
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2015)
Absence of RIPK3 predicts necroptosis resistance in malignant melanoma
P. Geserick et al.
CELL DEATH & DISEASE (2015)
Optimized Sleeping Beauty transposons rapidly generate stable transgenic cell lines
Eric Kowarz et al.
BIOTECHNOLOGY JOURNAL (2015)
Apoptosis resistance, mitotic catastrophe, and loss of ploidy control in Burkitt lymphoma
Cindrilla Chumduri et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2015)
The XIAP inhibitor Embelin enhances TRAIL-induced apoptosis in human leukemia cells by DR4 and DR5 upregulation
Rong Hu et al.
TUMOR BIOLOGY (2015)
TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells
Susann Voigt et al.
BMC CANCER (2014)
SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome
Carmen S. Tellez et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors
Jeffrey R. Infante et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Mixed Lineage Kinase Domain-like Protein MLKL Causes Necrotic Membrane Disruption upon Phosphorylation by RIP3
Huayi Wang et al.
MOLECULAR CELL (2014)
Regulated necrosis: the expanding network of non-apoptotic cell death pathways
Tom Vanden Berghe et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
RIP3 is downregulated in human myeloid leukemia cells and modulates apoptosis and caspase-mediated p65/RelA cleavage
A-L Nugues et al.
CELL DEATH & DISEASE (2014)
Reversion of apoptotic resistance of TP53-mutated Burkitt lymphoma B-cells to spindle poisons by exogenous activation of JNK and p38 MAP kinases
M. Farhat et al.
CELL DEATH & DISEASE (2014)
Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism
Jennifer L. Allensworth et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
The mechanism of necroptosis in normal and cancer cells
Simone Fulda
CANCER BIOLOGY & THERAPY (2013)
CAPE promotes TRAIL-induced apoptosis through the upregulation of TRAIL receptors via activation of p38 and suppression of JNK in SK-Hep1 hepatocellular carcinoma cells
Eun Young Kim et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase
Liming Sun et al.
CELL (2012)
The RIP1/RIP3 Necrosome Forms a Functional Amyloid Signaling Complex Required for Programmed Necrosis
Jixi Li et al.
CELL (2012)
TRAIL Signaling and Synergy Mechanisms Used in TRAIL-Based Combination Therapies
Christian T. Hellwig et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Targeting IAP proteins for therapeutic intervention in cancer
Simone Fulda et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib
D. Lecis et al.
BRITISH JOURNAL OF CANCER (2010)
A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB
Yao Dai et al.
BMC CANCER (2009)
Phosphorylation-Driven Assembly of the RIP1-RIP3 Complex Regulates Programmed Necrosis and Virus-Induced Inflammation
YoungSik Cho et al.
CELL (2009)
Receptor Interacting Protein Kinase-3 Determines Cellular Necrotic Response to TNF-α
Sudan He et al.
CELL (2009)
RIP3, an Energy Metabolism Regulator That Switches TNF-Induced Cell Death from Apoptosis to Necrosis
Duan-Wu Zhang et al.
SCIENCE (2009)
cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination
Mathieu J. M. Bertrand et al.
MOLECULAR CELL (2008)
Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients
Catherine Patte et al.
BLOOD (2007)
Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma
S Tafuku et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule
N Holler et al.
NATURE IMMUNOLOGY (2000)
分享论文
